Physician profile
Paul Barone
NPI 1124004346
$8,928.61
in general payments reported to CMS, 2019-2025
39 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,807 · 2020: $123 · 2021: $1,065 · 2022: $1,247 · 2023: $1,178 · 2024: $1,026 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,686.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,738.95 | 2019 | |
| Amgen INC. | $964.96 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $589.62 | 2021-2023 | Optimizer |
| Merck Sharp & Dohme LLC | $574.96 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $480.60 | 2019-2024 | Xarelto |
| Pfizer INC. | $411.00 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $389.49 | 2019-2024 | Livalo |
| Novartis Pharmaceuticals Corporation | $387.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $353.00 | 2021-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $313.00 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $291.09 | 2019-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $272.67 | 2021-2025 | Onpattro |
| Esperion Therapeutics, INC. | $247.37 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $235.32 | 2019-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $228.00 | 2019-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Barone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.